Dallas, TX Clinical Trials Report — April 2026

For Dallas residents considering participation in clinical research, April 2026 presents important opportunities, particularly for those looking to join trials before enrollment concludes. Across Dallas, 90 clinical trials are slated to close within the next 90 days. This urgency is especially relevant for healthy volunteers, as 7 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Currently, Dallas, TX is a bustling hub for medical research, with 1,456 clinical trials actively recruiting across 658 research facilities. This month saw the opening of 15 new trials, a decrease from the 28 trials that launched in March 2026, but still offering fresh avenues for participation.

New Research Opportunities in Dallas

April brings several significant new trials to Dallas, including notable Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is sponsoring NCT07533175, "AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight." This Phase 3 study, aiming for 630 participants, investigates the safety and effectiveness of NNC0487-0111, taken as a weekly injection, for individuals with excess body weight and type 2 diabetes.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07509307, "AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain." This trial seeks 400 participants to compare the safety and effect of NNC0487-0111 against a placebo for those with excess body weight and knee osteoarthritis.
• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy.
• Kinaset Therapeutics Inc is initiating NCT07532265, "A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma." This dose-ranging study will evaluate Frevecitinib over a 12-week treatment period in 512 patients whose severe asthma is not controlled with standard medication.
• Boehringer Ingelheim is sponsoring NCT07544654, "A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy." This Phase 3 study aims to determine if obrixtamig combined with standard chemotherapy improves survival for 390 adults with advanced extrapulmonary neuroendocrine cancer.
• Housey Healthcare ULC is leading NCT07546929, "HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes." This Phase 2 study with 300 participants will investigate HP-211 for its potential to help control blood sugar levels in people with type 2 diabetes.

New trials this month are exploring a range of conditions, with 2 focused on overweight, 2 on obesity, and individual trials for cancer, cardiac amyloidosis, castration-resistant prostate cancer (CRPC), cirrhosis, COVID-19, diabetes mellitus, and ER+, HER2- breast cancer. The majority of new studies are drug trials, with 11 new drug trials, followed by 3 other types of studies, 2 device trials, 1 biological, 1 genetic, and 1 procedure trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical research. Of the 15 new trials launched this month, 2 are actively seeking healthy volunteers. Across Dallas, a total of 126 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical advancements.

Dallas's Leading Research Facilities

Dallas is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Texas Southwestern Medical Center (177 trials)
• UT Southwestern Medical Center (155 trials)
• UT Southwestern/Simmons Cancer Center-Dallas (92 trials)
• University of Texas Southwestern (58 trials)
• Research Site (43 trials)
• Baylor University Medical Center (33 trials)
• Parkland Memorial Hospital (33 trials)
• Mary Crowley Cancer Research (30 trials)
• Medical City Dallas Hospital (28 trials)
• Retina Foundation of the Southwest (23 trials)
• UT Southwestern (21 trials)
• UT Southwestern Simmons Cancer Center - RedBird (21 trials)

These institutions offer a broad spectrum of research, with UT Southwestern facilities playing a dominant role, particularly in cancer research through the Simmons Cancer Center. Baylor University Medical Center and Parkland Memorial Hospital also contribute significantly to the city's research landscape.

Trials Closing Soon: Conditions Affected

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cardiovascular, oncological, and respiratory conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Coronary artery disease (4 trials)
• Bladder cancer (3 trials)
• Gastroesophageal junction adenocarcinoma (2 trials)
• Deep venous thrombosis (2 trials)
• Heart failure (2 trials)
• Interstitial lung disease (2 trials)
• Advanced solid tumor (2 trials)
• Brachycephaly (2 trials)
• Breast cancer (2 trials)
• Deformational plagiocephaly (2 trials)

Expanding Your Search: Nearby Texas Cities

While Dallas offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Texas. Cities with active trials include Houston (26 trials), San Antonio (15 trials), Austin (8 trials), Fort Worth (4 trials), Galveston (3 trials), Irving (2 trials), Plano (2 trials), and Katy (1 trial). Exploring these neighboring cities can broaden the scope of available research options.

Participation in clinical trials is open to a diverse range of individuals. Of the 15 new trials launched this month, 14 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials are specifically designed to include children. Academic institutions, notably the University of Texas Southwestern Medical Center, continue to play a vital role in Dallas's research ecosystem, alongside industry sponsors like Novo Nordisk A/S and Incyte Corporation, who are driving significant research efforts.

As we move through April, the focus remains on the ongoing enrollment in these significant Phase 2 and 3 trials and the continued exploration of new therapeutic strategies, with Dallas's robust research community at the forefront of medical innovation.